BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chronic Spontaneous Urticaria readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Chronic Spontaneous U
 rticaria\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07613866-11104@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-3095: Phase 2 readout est. (NCT07613866)
DESCRIPTION:HRS-3095\, phase 2\, Chronic Spontaneous Urticaria.\nStudy: A C
 linical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/hrs-3095#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07613866
URL:https://assetmemo.bio/drug/hrs-3095#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868212-1415@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06868212)
DESCRIPTION:remibrutinib\, phase 3\, Chronic Spontaneous Urticaria.\nStudy:
  A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Ear
 ly Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Co
 ntrolled by Second Generation H1-antihistamines\nEstimated primary complet
 ion: 22 February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/remibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06868212
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865651-1415@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270823
DTEND;VALUE=DATE:20270824
SUMMARY:remibrutinib: Phase 2 readout est. (NCT06865651)
DESCRIPTION:remibrutinib\, phase 2\, Chronic Spontaneous Urticaria.\nStudy:
  Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its
  Mechanism of Action in Participants With Chronic Urticaria\nEstimated pri
 mary completion: 23 August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/remibrutinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06865651
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816328-1415@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07816328)
DESCRIPTION:remibrutinib\, phase 3\, Chronic Spontaneous Urticaria.\nStudy:
  Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm
  in Adult Patients With Chronic Spontaneous Urticaria Inadequately Control
 led by H1-antihistamines Within 24 Weeks\nEstimated primary completion: 24
  May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remibrutin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7816328
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816328-5789@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:Xolair (Omalizumab): Phase 3 readout est. (NCT07816328)
DESCRIPTION:Xolair (Omalizumab)\, phase 3\, Chronic Spontaneous Urticaria.\
 nStudy: Investigation of a Remibrutinib- and Omalizumab-based Treatment Al
 gorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately 
 Controlled by H1-antihistamines Within 24 Weeks\nEstimated primary complet
 ion: 24 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/oma
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07816328
URL:https://assetmemo.bio/drug/omalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256392-1321@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:barzolvolimab: Phase 3 readout est. (NCT07256392)
DESCRIPTION:barzolvolimab\, phase 3\, Chronic Spontaneous Urticaria.\nStudy
 : Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in 
 Participants With Chronic Spontaneous Urticaria\nEstimated primary complet
 ion: September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 barzolvolimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07256392
URL:https://assetmemo.bio/drug/barzolvolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07875426-1281@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:AK139: Phase 2 readout est. (NCT07875426)
DESCRIPTION:AK139\, phase 2\, Chronic Spontaneous Urticaria.\nStudy: A Tria
 l to Evaluate the Efficacy and Safety of AK139 in Participants With Chroni
 c Spontaneous Urticaria\nEstimated primary completion: 8 January 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ak139#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07875426
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
